Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2021 Dec 14;11:823960. doi: 10.3389/fonc.2021.823960

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Yuan-Hung Kuo 1, Sheng-Nan Lu 1, Yen-Yang Chen 2, Kwong-Ming Kee 1, Yi-Hao Yen 1, Chao-Hung Hung 1, Tsung-Hui Hu 1, Chien-Hung Chen 1, Jing-Houng Wang 1,*
PMCID: PMC8712880  PMID: 34970502

In the original article, there was an error. The IRB Number of our article, “IRB No: 202100961B0”, was typed mistakenly as “IRB No: 20210096B0”.

A correction has been made to the last sentence of the Materials and Methods , Patients and the Ethics Statement ”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES